Mr. Spangler joined the Company as a director in March 2018. Since February 2025, Mr. Spangler has been Chief Financial Officer and a director of Cancer Response Team, Inc., a nonprofit organization dedicated to helping children get supportive cancer care. Previously, from October 2020 to February 2025, Mr. Spangler served as Chief Financial Officer of On Target Laboratories, LLC, a developer of fluorescent markers used to illuminate cancer during surgery. From March 2020 to September 2020, Mr. Spangler served as Chief Financial Officer of MHC Software, LLC, a supplier of document automation software. Prior to these roles, Mr. Spangler served as Chief Financial Officer of VigiLanz Corporation, a digital healthcare intelligence company, from September 2014 to October 2019; Chief Financial Officer of Healthland, Inc., an electronic health records company serving critical access hospitals, from August 2012 to August 2014; and Senior Vice President and Chief Financial Officer of Epocrates, Inc., a publicly traded provider of point-of-care medical applications, from October 2010 to August 2012. Mr. Spangler also acted as Operating Partner and CFO Advisor at Three Fields Capital, L.P., a private equity and venture capital firm, from April 2010 to October 2010, and as Chief Financial Officer of HighJump Software, LLC, a global provider of supply chain management software, from June 2009 to April 2010. Earlier in his career, Mr. Spangler was Senior Vice President and Chief Financial Officer of ev3 Inc., a publicly traded global endovascular company, from March 2005 to January 2009; Executive Vice President and Chief Financial Officer of EMPI, Inc., a medical device manufacturer, from July 1997 to March 2005; and held various senior finance leadership roles at Medtronic, Inc., a global medical device company, for over eleven years. Mr. Spangler currently serves on the board of directors of Cancer Response Team, Inc., and Lifespace Communities, Inc., which owns and operates 15 CCRCs in eight states and houses more than 5100 residents. He previously was a member of the board of directors of Urologix, Inc., a publicly traded medical device company, from August 2010 to February 2016. Mr. Spangler has over 35 years of experience in financial management, operations, mergers and acquisitions, and capital markets transactions in the medical device and healthcare IT industries. Mr. Spangler is qualified to serve on our Board because of his extensive executive skills and background in the healthcare industry and his expertise in finance.